Related Experiment Video
Updated: Mar 26, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Cancer immunology and canine malignant melanoma: A comparative review
Matthew J Atherton1, Joanna S Morris2, Mark R McDermott3
1McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada.
Abstract:
Oral canine malignant melanoma (CMM) is a spontaneously occurring aggressive tumour with relatively few medical treatment options, which provides a suitable model for the disease in humans. Historically, multiple immunotherapeutic strategies aimed at provoking both innate and adaptive anti-tumour immune responses have been published with varying levels of activity against CMM. Recently, a plasmid DNA vaccine expressing human tyrosinase has been licensed for the adjunct treatment of oral CMM. This article reviews the immunological similarities between CMM and the human counterpart; mechanisms by which tumours evade the immune system; reasons why melanoma is an attractive target for immunotherapy; the premise of whole cell, dendritic cell (DC), viral and DNA vaccination strategies alongside preliminary clinical results in dogs. Current "gold standard" treatments for advanced human malignant melanoma are evolving quickly with remarkable results being achieved following the introduction of immune checkpoint blockade and adoptively transferred cell therapies. The rapidly expanding field of cancer immunology and immunotherapeutics means that rational targeting of this disease in both species should enhance treatment outcomes in veterinary and human clinics.
Insights
Oral canine malignant melanoma (CMM) offers insights into human melanoma immunotherapy. Research reviews immune strategies and vaccination for CMM, enhancing treatment for both canine and human patients.
Area of Science:
- Comparative oncology
- Immunology
- Veterinary medicine
Background:
- Oral canine malignant melanoma (CMM) is an aggressive tumor with limited treatment options, serving as a valuable model for human melanoma.
- Immunotherapy has shown variable success in CMM, prompting exploration of novel strategies.
- Recent advancements include licensed DNA vaccines for CMM adjunct treatment.
Purpose of the Study:
- To review immunological similarities between CMM and human melanoma.
- To explore tumor immune evasion mechanisms and melanoma's suitability for immunotherapy.
- To evaluate various vaccination strategies (whole cell, dendritic cell, viral, DNA) and their clinical outcomes in dogs.
Main Methods:
- Review of existing literature on CMM immunology and immunotherapy.
- Analysis of different vaccination strategies and their preliminary clinical results in canine models.
- Comparison of CMM treatment with current human malignant melanoma therapies.
Main Results:
- Immunological parallels exist between CMM and human melanoma.
- Various immunotherapy approaches, including DNA vaccination, have demonstrated activity against CMM.
- Current human treatments involve immune checkpoint blockade and adoptive cell therapies.
Conclusions:
- CMM is a relevant model for studying melanoma immunotherapy.
- Understanding tumor immunology and employing rational immunotherapeutic strategies can improve outcomes in both veterinary and human medicine.
- The expanding field of cancer immunology offers promising avenues for CMM and human melanoma treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...